GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Coded Growth Innovation Center DMSI · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Coded Growth Innovation Center

Its shares trade under the ticker DMSI. It has been listed since 11 July 2003.

Dermisonics, Inc. engages in the provision of medical technology services. The company is headquartered in Henderson, Nevada. The company went IPO on 2003-07-11. The Company’s principal activity is to provide drugs delivery system. Its Transdermal systems deliver drugs through the skin into the bloodstream. Medications delivered via skin patches avoid liver metabolism, a necessary feature for drug molecules to metabolize easily, and allows for lower dosing of medications. There are two types of transdermal delivery systems: passive and active. In passive transdermal systems, the drug diffuses through the skin where it can act locally or penetrate the capillaries for systemic effect. Active patches require a physical force to facilitate the movement of drug molecules across the skin. The company is a development stage company.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
11 Jul 2003

Leadership

Pay as last reported

  • Mr. Bruce HaglundChairman of the Board, Interim Chief Executive Officer, Interim Chief Financial Officer
  • Grant AtkinsDirector
  • Mr. Bruce ReddingDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Dermisonics provides transdermal drug delivery systems avoiding liver metabolism for lower dosing.
  • Passive transdermal systems allow local or systemic drug effects through skin diffusion.
  • Active patches use physical force for enhanced drug molecule movement across skin.

Weaknesses

  • Dermisonics is a development stage company with limited market presence.
  • Transdermal systems require specific drug molecules that metabolize easily.
  • The company's focus on transdermal delivery limits broader medical technology applications.

Opportunities

  • Growth in Health Care sector for transdermal drug delivery systems in the US market.
  • Increasing demand for passive transdermal systems in medical technology services.
  • Expanding use of active patches in drug delivery systems for systemic effects.

Threats

  • Competition from established medical technology companies in Health Care sector.
  • Regulatory challenges in drug delivery system approvals within US market.
  • Dependence on specific drug molecules that metabolize easily for system effectiveness.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.